Browse the evidence

Genetic predisposition to higher BMI does not predict weight regain after weight loss.

Genetic factors related to BMI may not be useful for predicting weight regain, focusing instead on abdominal obesity genetics.

Genetic effects on abdominal obesity may be more pronounced than those on general obesity during weight regain.

Understanding the differential impact of genetics on abdominal versus general obesity can inform targeted interventions.

Remission of diabetes may not be permanent and can result in glycemic relapse over time.

Clinicians should communicate the potential for relapse when discussing remission with patients.

NN1706 lowers body weight & improves glycemic control in obese rodents and monkeys.

NN1706 may also be beneficial for weight management and glycemic control in animal models of obesity.

Increased heart rate was observed across NN1706 treatment cohorts.

Clinicians should monitor heart rate in patients receiving NN1706 treatment.

The most common components of metabolic syndrome in the cohort were abdominal obesity and elevated blood pressure.

Understanding common MetS components can guide targeted interventions.

Challenges with GLP-1s include side effects, nutritional deficiencies, and low long-term adherence.

Clinicians should be aware of and manage these challenges when prescribing GLP-1s.

In postmenopausal females with type 2 diabetes, an intensive lifestyle intervention decreased estradiol levels by 15% and bioavailable testosterone by 13% at year 1.

Practitioners should consider the hormonal changes in females when implementing weight loss interventions.

Sleep restriction reduced fat oxidation during high-dose insulin infusion in postmenopausal women.

Practitioners should be aware that sleep restriction may impair fat oxidation in this population.

Low energy availability did not enhance performance when expressed relative to body mass.

Performance assessments should consider body mass to accurately evaluate the effects of energy availability.

No evidence of a relationship was found between RIR accuracy and biological sex, years of RT experience, or relative bench press strength.

RIR accuracy can be considered independent of these demographic and experiential factors.

GLP-1 receptor agonists were originally developed as glucose lowering agents.

Understanding the original purpose of GLP-1 receptor agonists can inform their use in weight management.

Tirzepatide has similar gastrointestinal adverse reactions and contraindications as traditional GLP-1 receptor agonists.

Clinicians should be aware of the potential for similar side effects when prescribing tirzepatide.

Rapid weight loss induced by semaglutide can lead to noticeable facial volume loss and the appearance of a prematurely aged face, referred to as 'Ozempic face.'

Healthcare providers should be aware of the potential cosmetic implications of semaglutide use for weight loss.

The characteristics of 'Ozempic face' occur in people much younger than what is seen with the natural aging process.

Clinicians should consider age-related factors when assessing patients for semaglutide treatment.

Intranasal delivery of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could overcome the limitations of subcutaneous administration for obesity treatment.

Practitioners should consider intranasal delivery methods for improving patient adherence and reducing side effects.

Innovative approaches for nasal delivery of GLP-1 RAs show promising preclinical results.

Practitioners should consider these innovative approaches to enhance the effectiveness of GLP-1 RA delivery.

GB participants used fewer glucose-lowering medications at 10 years, but HbA1c, fasting glucose, calculated cardiovascular risk, quality-of-life, and incident diabetes complications did not differ significantly between the groups.

While GB surgery may reduce the need for glucose-lowering medications, it does not significantly improve other health metrics.

Obesity accompanies an increasing burden of metabolic disease among people living with HIV (PWH).

Healthcare providers should be aware of the increased risk of metabolic diseases in PWH with obesity.

Contemporary antiretroviral therapy (ART) regimens, particularly integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF), are contributors to weight gain and obesity in PWH.

Clinicians should consider the impact of specific ART regimens on weight management in PWH.

Metabolic dysregulation is linked to ectopic fat deposition and alterations in immune cell populations in adipose tissue among PWH.

Understanding these links can help in developing targeted interventions for obesity in PWH.

Semaglutide may improve wait-list times for renal transplantation by overcoming obesity as a barrier.

Addressing obesity in patients may facilitate their eligibility for renal transplantation.

Gender, household size, and education were associated with GLP-1 use and interest.

Marketers should consider demographic factors when targeting potential GLP-1 consumers.

The therapeutic efficacy of poly-agonists is likely to change the treatment paradigm for obesity.

Healthcare providers may need to adapt to new treatment protocols involving poly-agonists.